Quotient (QTNT) versus Its Competitors Head-To-Head Survey

Quotient (NASDAQ: QTNT) is one of 24 public companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare Quotient to related businesses based on the strength of its valuation, analyst recommendations, earnings, profitability, dividends, risk and institutional ownership.

Volatility & Risk

How to Become a New Pot Stock Millionaire

Quotient has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Quotient’s rivals have a beta of 1.44, meaning that their average share price is 44% more volatile than the S&P 500.


This table compares Quotient and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quotient -342.23% N/A -64.90%
Quotient Competitors -884.88% -64.84% -17.51%

Analyst Ratings

This is a summary of current ratings and recommmendations for Quotient and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quotient 0 0 2 0 3.00
Quotient Competitors 101 367 567 19 2.48

Quotient currently has a consensus target price of $11.50, indicating a potential upside of 175.12%. As a group, “Diagnostic substances” companies have a potential upside of 13.45%. Given Quotient’s stronger consensus rating and higher possible upside, research analysts clearly believe Quotient is more favorable than its rivals.

Earnings and Valuation

This table compares Quotient and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Quotient $22.23 million -$85.06 million -1.38
Quotient Competitors $308.35 million $18.66 million -39.62

Quotient’s rivals have higher revenue and earnings than Quotient. Quotient is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

63.8% of Quotient shares are owned by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are owned by institutional investors. 29.0% of Quotient shares are owned by company insiders. Comparatively, 13.5% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Quotient beats its rivals on 7 of the 12 factors compared.

About Quotient

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply